Combined Ophthalmic Artery and Central Retinal Vein Occlusion Secondary to Advanced Mantle Cell Lymphoma.
Sign Up to like & getrecommendations! Published in 2022 at "JAMA ophthalmology"
DOI: 10.1001/jamaophthalmol.2022.3230
Abstract: This case report describes a diagnosis of ophthalmic artery and central retinal vein occlusion in a female patient with a history of end-stage mantle cell lymphoma. read more here.
Keywords: central retinal; vein occlusion; artery central; ophthalmic artery ... See more keywords
Bortezomib consolidation or maintenance following immunochemotherapy and autologous stem cell transplantation for mantle cell lymphoma: CALGB/Alliance 50403
Sign Up to like & getrecommendations! Published in 2020 at "American Journal of Hematology"
DOI: 10.1002/ajh.25783
Abstract: Immunochemotherapy followed by autologous transplant (ASCT) in CALGB/Alliance 59909 achieved a median progression‐free survival (PFS) in mantle cell lymphoma (MCL) of 5 years, but late recurrences occurred. We evaluated tolerability and efficacy of adding post‐transplant bortezomib… read more here.
Keywords: pfs; calgb alliance; mantle cell; cell ... See more keywords
Mantle cell lymphoma in 2022 - A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments.
Sign Up to like & getrecommendations! Published in 2022 at "American journal of hematology"
DOI: 10.1002/ajh.26523
Abstract: The field of mantle cell lymphoma (MCL) has witnessed remarkable progress due to relentless advances in molecular pathogenesis, prognostication, and newer treatments. MCL consists of a spectrum of clinical subtypes. Rarely, atypical cyclin D1-negative MCL… read more here.
Keywords: cell lymphoma; mcl; molecular pathogenesis; mantle cell ... See more keywords
Real‐world outcomes of ibrutinib therapy in Korean patients with relapsed or refractory mantle cell lymphoma: a multicenter, retrospective analysis
Sign Up to like & getrecommendations! Published in 2021 at "Cancer Communications"
DOI: 10.1002/cac2.12150
Abstract: Dear Editor, Despite the introduction of novel front-line therapies including rituximab plus high-dose cytarabine followed by consolidative autologous stem cell transplantation (ASCT) and salvage therapy with bendamustine, lenalidomide or bortezomib, mantle cell lymphoma (MCL) is… read more here.
Keywords: ibrutinib therapy; outcomes ibrutinib; mantle cell; retrospective analysis ... See more keywords
Ibrutinib as monotherapy versus combination therapy in Chinese patients with relapsed/refractory mantle cell lymphoma: A multicenter study
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.4765
Abstract: Ibrutinib has revolutionized the treatment of mantle cell lymphoma (MCL). Both ibrutinib monotherapy and ibrutinib‐based combination therapy are important salvage options for patients with relapsed/refractory (R/R) MCL. The real‐world efficacy and safety profile of the… read more here.
Keywords: cell lymphoma; relapsed refractory; mantle cell; ibrutinib monotherapy ... See more keywords
Real-world treatment and outcome patterns of patients with mantle cell lymphoma in China: A large, multicenter retrospective analysis.
Sign Up to like & getrecommendations! Published in 2023 at "Cancer medicine"
DOI: 10.1002/cam4.6009
Abstract: BACKGROUND Mantle cell lymphoma (MCL) is an uncommon heterogeneous subtype of B cell non-Hodgkin lymphoma, and clinical features in MCL appear regional characteristics. MCL treatment opinions are not uniform between countries or regions within Asia… read more here.
Keywords: cell lymphoma; mantle cell; analysis; treatment ... See more keywords
Rituximab/bendamustine/cytarabine for transplant-eligible patients with mantle cell lymphoma: A retrospective study.
Sign Up to like & getrecommendations! Published in 2023 at "Cancer medicine"
DOI: 10.1002/cam4.6114
Abstract: BACKGROUND Mantle cell lymphoma is considered an aggressive B-cell lymphoma. The optimal induction regimen remains controversial as no randomized controlled trial has compared the efficacy of different induction therapies. METHOD Herein, we performed a retrospective… read more here.
Keywords: cell; rituximab bendamustine; cell lymphoma; bendamustine cytarabine ... See more keywords
Ofatumumab plus HyperCVAD/HD‐MA induction leads to high rates of minimal residual disease negativity in patients with newly diagnosed mantle cell lymphoma: Results of a phase 2 study
Sign Up to like & getrecommendations! Published in 2022 at "Cancer"
DOI: 10.1002/cncr.34106
Abstract: Ofatumumab is a humanized type 1 anti‐CD20 monoclonal antibody. Preclinical studies show improved complement‐mediated cytotoxicity (CMC) compared to rituximab in mantle cell lymphoma (MCL). This study evaluates the safety and efficacy of combining ofatumumab with… read more here.
Keywords: cell lymphoma; mantle cell; newly diagnosed;
POTENTIAL THERAPEUTIC ADVANTAGE FOR DUVELISIB IN MANTLE CELL LYMPHOMA: PI3Kδ AND OVEREXPRESSED PI3Kγ IN LYMPHOMA CELLS HAVE SPECIALIZED FUNCTIONAL ROLES
Sign Up to like & getrecommendations! Published in 2019 at "Hematological Oncology"
DOI: 10.1002/hon.194_2631
Abstract: (5) RNA-seq. The abundance of gene transcriptswas determined by RNA sequencing, using the Illumina HiSeq 2500 platform. (6) Proteomic studies were performed using data independent analysis (DIA) Liquid chromatography–mass spectrometry (LC/MS). (7) Data analysis. Omics… read more here.
Keywords: duvelisib mantle; analysis; therapeutic advantage; mantle cell ... See more keywords
Chronic lymphocytic leukemia with t(6;14) (p21;q32) CCND3‐IGH: CCND3 rearrangement does not necessarily define a cyclin D1‐negative mantle cell lymphoma
Sign Up to like & getrecommendations! Published in 2021 at "Hematological Oncology"
DOI: 10.1002/hon.2930
Abstract: Dear Editor, Mantle cell lymphoma can be distinguished from chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) by the status of its cyclin D1 expression and CCND1‐IGH fusion in the vast majority of the cases. Nevertheless, rare… read more here.
Keywords: cyclin negative; cell; cell lymphoma; mantle cell ... See more keywords
Use of BTK inhibitors with focus on ibrutinib in mantle cell lymphoma: an expert panel opinion statement.
Sign Up to like & getrecommendations! Published in 2022 at "Hematological oncology"
DOI: 10.1002/hon.2983
Abstract: The introduction of BTK inhibitors transformed the management of patients with mantle cell lymphoma (MCL). Ibrutinib, the first-in-class BTK inhibitor is now approved in more than 80 countries and there are over 20 new BTK… read more here.
Keywords: opinion statement; mantle cell; cell lymphoma; btk inhibitors ... See more keywords